LifeMD, Inc. (NASDAQ:LFMD) CEO Justin Schreiber Sells 50,000 Shares

LifeMD, Inc. (NASDAQ:LFMD) CEO Justin Schreiber sold 50,000 shares of LifeMD stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $7.55, for a total value of $377,500.00. Following the completion of the transaction, the chief executive officer now directly owns 2,653,715 shares of the company’s stock, valued at approximately $20,035,548.25. This represents a 1.85 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Justin Schreiber also recently made the following trade(s):

• On Thursday, January 2nd, Justin Schreiber sold 25,000 shares of LifeMD stock. The stock was sold at an average price of $5.19, for a total value of $129,750.00.
• On Monday, December 2nd, Justin Schreiber sold 25,000 shares of LifeMD stock. The stock was sold at an average price of $6.52, for a total value of $163,000.00.

LifeMD Stock Performance

Shares of NASDAQ LFMD traded down $2.06 during midday trading on Friday, hitting $5.46. 4,653,961 shares of the company’s stock traded hands, compared to its average volume of 882,281. LifeMD, Inc. has a 1 year low of $3.99 and a 1 year high of $12.88. The stock has a market capitalization of $236.47 million, a price-to-earnings ratio of -8.53 and a beta of 1.50. The firm has a fifty day moving average of $5.70 and a 200 day moving average of $5.40.

Institutional Investors Weigh In On LifeMD

Hedge funds and other institutional investors have recently made changes to their positions in the business. JPMorgan Chase & Co. increased its position in shares of LifeMD by 496.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 88,173 shares of the company’s stock valued at $462,000 after purchasing an additional 73,389 shares during the last quarter. State Street Corp increased its position in shares of LifeMD by 20.0% during the 3rd quarter. State Street Corp now owns 1,155,495 shares of the company’s stock valued at $6,055,000 after purchasing an additional 192,861 shares during the last quarter. Los Angeles Capital Management LLC increased its position in shares of LifeMD by 852.6% during the 3rd quarter. Los Angeles Capital Management LLC now owns 121,585 shares of the company’s stock valued at $637,000 after purchasing an additional 108,822 shares during the last quarter. Geode Capital Management LLC increased its position in shares of LifeMD by 11.4% during the 3rd quarter. Geode Capital Management LLC now owns 819,233 shares of the company’s stock valued at $4,293,000 after purchasing an additional 83,598 shares during the last quarter. Finally, Mirador Capital Partners LP increased its position in shares of LifeMD by 139.3% during the 4th quarter. Mirador Capital Partners LP now owns 106,059 shares of the company’s stock valued at $525,000 after purchasing an additional 61,731 shares during the last quarter. Hedge funds and other institutional investors own 35.52% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the company. Mizuho assumed coverage on LifeMD in a research report on Wednesday, December 4th. They issued a “neutral” rating and a $7.00 price target for the company. KeyCorp decreased their target price on LifeMD from $10.00 to $7.00 and set an “overweight” rating for the company in a research report on Wednesday, January 8th. HC Wainwright reissued a “buy” rating and issued a $12.00 target price on shares of LifeMD in a research report on Monday, November 11th. Finally, Lake Street Capital started coverage on LifeMD in a research report on Tuesday, December 10th. They issued a “buy” rating and a $12.00 target price for the company. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $11.14.

LifeMD Company Profile

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.